SBIR/STTR Research Award

Novel Cleavable Nucleotides for DNA Sequencing by Synthesis

Award identifier eb4eb65083accb6c3b100ec1fab07252b5ba65c5baa2b275fa337c58c0eeaa1cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$162,574

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INTELLIGENT BIO-SYSTEMS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Intelligent Bio-Systems is developing a high-speed, low-cost DNA sequencing-by-synthesis (SBS) system which is based on the use of cleavable fluorescent nucleotides with reversible terminator technology. The cleavable l inkers utilized in these nucleotides enable efficient removal of fluorescent signals and the reversible terminator technology enables reliable sequencing of repeats. In order to extend the performance of the sequencing system, we believe it is important to minimize the effect of residual linker on the nucleotide bases left behind after cleavage. These residual linkers may disturb the DNA duplex structure and interfere with a polymerase's ability to incorporate subsequent nucleotides. The goal of this Phase I project is to synthesize and evaluate several novel cleavable nucleotides which generate minimal residues after cleavage. We anticipate that the use of such nucleotides should result in much higher cumulative cycle efficiency in the SBS and enable longer sequencing reads. During Phase I of this project we will synthesize, characterize and extensively evaluate two novel designs of nucleotides which will generate smaller residues after fluorescent signal removal. The performance of novel nucleotides will be compared with the performance of our standard design cleavable nucleotides in solution and on solid surfaces. During Phase II we will synthesize and characterize 4 nucleotides based on the best performing analogs and perform synthesis optimization and scale-up. Phase II will also involve evaluation of all 4 nucleotides in our sequencing instrument. Ultimately, the ability to produce very inexpensive detailed DNA sequence information for complex organisms' genomes will both lead to accelerated disco veries throughout biology and provide the basis for Pharmacogenomics, a new paradigm in therapeutics wherein medicines are prescribed based on individual genotypes rather than just observed symptoms.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.